大洋生物
(003017)
| 流通市值：21.64亿 | | | 总市值：26.23亿 |
| 流通股本：6928.80万 | | | 总股本：8400.00万 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 278,128,254.27 | 1,045,439,587.88 | 747,305,412.73 | 499,310,379.08 |
| 营业收入 | 278,128,254.27 | 1,045,439,587.88 | 747,305,412.73 | 499,310,379.08 |
| 二、营业总成本 | 247,566,318.08 | 941,878,108.45 | 668,570,639.15 | 442,861,186.78 |
| 营业成本 | 212,882,272.71 | 806,050,789.68 | 570,929,692.37 | 377,945,296.92 |
| 税金及附加 | 2,377,527.23 | 9,378,061.53 | 6,924,330.72 | 4,418,107.6 |
| 销售费用 | 2,352,340.85 | 11,616,828.19 | 8,192,631.5 | 5,746,198.28 |
| 管理费用 | 21,175,680.53 | 75,200,728.66 | 57,893,992.78 | 39,318,244.97 |
| 研发费用 | 9,057,135.16 | 43,777,617.57 | 27,695,023.89 | 17,273,842.28 |
| 财务费用 | -278,638.4 | -4,145,917.18 | -3,065,032.11 | -1,840,503.27 |
| 其中:利息费用 | 785,640.18 | 4,290,748.64 | 3,371,603.38 | 2,430,852.05 |
| 其中:利息收入 | 2,408,094.86 | 8,919,647.71 | 6,441,764.33 | 4,074,837.3 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 44,728.43 | -1,463,335.26 | -69,624.24 | 296,228.9 |
| 加:投资收益 | -167,785.07 | 1,179,572.46 | -774,165.39 | -1,121,628.15 |
| 资产处置收益 | -21,124.68 | 2,049,686.99 | 15,787.61 | - |
| 资产减值损失(新) | -238,840.75 | -18,159,797.31 | -14,055,437.73 | -13,797,792.73 |
| 信用减值损失(新) | -2,040,079.32 | -781,223.62 | -541,569.53 | 118,049.97 |
| 其他收益 | 6,660,184.98 | 23,785,748.5 | 20,554,807.23 | 14,817,071.15 |
| 四、营业利润 | 34,799,019.78 | 110,172,131.19 | 83,864,571.53 | 56,761,121.44 |
| 加:营业外收入 | 4,704.13 | 276,718.59 | 99,035.05 | 78,630.45 |
| 减:营业外支出 | 44,126.03 | 3,597,394.35 | 1,883,182.41 | 2,202,276.17 |
| 五、利润总额 | 34,759,597.88 | 106,851,455.43 | 82,080,424.17 | 54,637,475.72 |
| 减:所得税费用 | 3,855,725.63 | 6,787,143.78 | 2,421,380.2 | 4,341,508 |
| 六、净利润 | 30,903,872.25 | 100,064,311.65 | 79,659,043.97 | 50,295,967.72 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 30,903,872.25 | 100,064,311.65 | 79,659,043.97 | 50,295,967.72 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 30,870,752.17 | 99,854,406.02 | 80,036,566 | 50,505,565.27 |
| 少数股东损益 | 33,120.08 | 209,905.63 | -377,522.03 | -209,597.55 |
| 扣除非经常损益后的净利润 | 28,426,833.33 | 92,754,003.95 | 74,983,571.02 | 46,760,916.19 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.38 | 1.23 | 0.98 | 0.62 |
| (二)稀释每股收益 | 0.38 | 1.21 | 0.98 | 0.62 |
| 九、综合收益总额 | 30,903,872.25 | 100,064,311.65 | 79,659,043.97 | 50,295,967.72 |
| 归属于母公司股东的综合收益总额 | 30,870,752.17 | 99,854,406.02 | 80,036,566 | 50,505,565.27 |
| 归属于少数股东的综合收益总额 | 33,120.08 | 209,905.63 | -377,522.03 | -209,597.55 |
| 公告日期 | 2026-04-28 | 2026-04-28 | 2025-10-21 | 2025-08-26 |
| 审计意见(境内) | | 标准无保留意见 | | |